SAGE – sage therapeutics, inc. (US:NASDAQ)
Stock Stats
News
11/21
01:30 pm
sage
Low
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]
11/21
12:32 pm
sage
Low
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]
11/21
12:24 pm
sage
Low
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.
11/21
08:05 am
sage
Low
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
11/20
01:16 pm
sage
Low
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
10/29/2024
04:05 pm
SAGE
-24.1%
MISS
7/31/2024
04:05 pm
SAGE
-10.9%
MISS
4/25/2024
06:30 am
SAGE
-5.1%
MISS
2/14/2024
06:30 am
SAGE
6.5%
BEAT
11/21
08:05 am
Upgrades
Underperform
Sector Perform
Royal Bank of Canada
Low
-1.2%
11/21
08:05 am
Upgrades
Underperform
Sector Perform
Royal Bank of Canada
Low
-1.2%
11/21
04:51 am
Upgrades
Underperform
Sector Perform
RBC Capital
Low
-1.8%
11/21
04:51 am
Upgrades
Underperform
Sector Perform
RBC Capital
Low
-1.8%
11/20
01:16 pm
Reiterates
Neutral
Neutral
HC Wainwright
Low
2.2%
11/20
06:40 am
sage
High
Form 8-K Sage Therapeutics, Inc. For: Nov 20
11/14
06:15 pm
sage
Medium
Form SC 13G/A Sage Therapeutics, Inc. Filed by: BB BIOTECH AG
11/14
04:43 pm
sage
Medium
Form 4 Sage Therapeutics, Inc. For: Nov 01 Filed by: Benecchi Christopher
11/12
04:56 pm
sage
Low
Form SC 13G/A Sage Therapeutics, Inc. Filed by: VANGUARD GROUP INC
11/12
10:35 am
sage
Medium
Form SC 13G/A Sage Therapeutics, Inc. Filed by: FMR LLC
Show more
Top News Gainers
2/29 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 13.5%
3/13 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.8%
4/3 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 9.3%
12/10 Form 4 Sage Therapeutics, Inc. For: Dec 09 Filed by: IGUCHI KIMI 9.2%
4/19 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. 8.7%
12/5 Sage's oral depression therapy fails in late-stage trial; shares plunge [Reuters (UK)] 8.5%
12/5 SAGE Therapeutics Inc (NASDAQ: SAGE) had its price target lowered by analysts at Guggenheim from $200.00 to $110.00. They now have a "buy" rating on the stock. 7.1%
12/11 Sage Therapeutics: Insider Buying After Recent Debacle [Seeking Alpha] 5.8%
6/27 Sage Therapeutics to Host “Sage FutureCast” Webcast 5.4%
11/1 SAGE Therapeutics Inc (NASDAQ: SAGE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.1%
Top News Decliners
12/5 Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy ? [Yahoo! Finance News] -59.7%
3/11 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $58.00 price target on the stock. -19.3%
2/27 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $69.00 price target on the stock. -17.4%
3/18 SAGE Therapeutics Inc (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. -12.5%
2/27 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics (SAGE) Investors With 100K+ Losses to Contact Its Attorneys: Firm Investigating Potential Securities Fraud -12.1%
8/30 Tocqueville Opportunity Is One Of The Best Mid-Cap Funds This Year [Forbes] -6.3%
12/16 Sage: In Need Of Authentic Smudging [Seeking Alpha] -6.0%
3/20 SAGE Therapeutics Inc (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $28.00 price target on the stock. -5.4%
3/5 SAGE Therapeutics Inc (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.1%
3/4 Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -4.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3